Maryland's COVID-19 Vaccine Boosts Adults in Korea and Switzerland

Maryland-based Novavax Inc. recently announced new international authorizations for its U.S. FDA-approved Nuvaxovid™ (NVX-CoV2373) vaccine.

On October 10, 2022, the company announced that Switzerland's Federal Office of Public Health (FOPH) had recommended Nuvaxovid as a heterologous and homologous booster for active immunization to prevent COVID-19 caused by the SARS-CoV-2 in adults. 

The FOPH now recommends using Nuvaxovid as an adult booster regardless of previous vaccine history.

And Novavax announced yesterday that its partner, SK bioscience, has submitted a Post Approval Change Application to the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid for use as a similar booster for adults.

KMFDS approved Nuvaxovid for use in adults in January 2022 and for use in adolescents aged 12 through 17 in July 2022.

Separately, Stanley Erck, President and CEO of Novavax, stated in a media release and commented to the European Parliament – COVI Committee Hearing on October 10, 2022, "We know that vaccines don't save lives, vaccinations do."

"To realize the benefits of vaccines, there must be robust uptake."

"Critical to uptake is both access and availability of COVID-19 vaccines, as well as public confidence in the safety and efficacy of these products. And to that end, Novavax is committed to transparency and accountability."

"Our company has been transparent around our clinical trial protocols and scientific data, which we believe is one of the best ways to ensure public confidence in any vaccine that is ultimately authorized and recommended for use."

"We also know that pandemics don't observe country borders."

"And although there is a worldwide surplus of COVID-19 vaccines, this will not always be the case."

"Novavax is committed to reasonable pricing, equitable distribution and allocation, and expansive vaccine access."

Nuvaxovid is also available in the European Union, Japan, Australia, New Zealand, and Israel as a booster and is actively under review in other countries. Nuvaxovid is the only protein-based COVID-19 vaccine currently available in the EU and the U.S.

Note: The trade name Nuvaxovid™ has not been approved by the U.S. FDA. And this news article was manually curated for mobile readers and is not paid content.